This page contains a Flash digital edition of a book.
ALIAXIN SR In those cases in which the aim was to restore shape and symmetry combined with a major re-toning effect, ALIAXIN® SR was used. The special feature of this product is the presence of a two-fold effect on the tissues. Thanks to the presence of a gel made up of monophasic hyaluronic acid with 500 kDa, 1000 kDa and 2000 kDa chains, it is possible to achieve an excellent lifting effect of the cutaneous wrinkles and a bio-restructuring effect with the promotion of neocollagenesis. On the other hand, as a result of the presence of 10% natural hyaluronic acid, a significant anti-ageing and hydrating effect is achieved, with maximum results visible in the weeks following treatment. The fluidity of ALIAXIN® SR allows homogeneous diffusion in the tissue, for a therapeutic approach to extended areas of the face, and an increase in the tone, firmness and elasticity of the skin.


ALIAXIN GP In the event of volumetric increases, the dermal filler ALIAXIN® GP was used, made up of highly cross-linked 1000 kDa and 2000 kDa hyaluronic acid-based gel, suitable for the restoration of volume, and to rebuild the areas that have been affected by atrophy. The high level of cross-linking in ALIAXIN® GP increases its duration in the tissues, allowing a significant increase in the volume of the tissues where injected. In the authors’ clinical practice,


ALIAXIN® GP has mainly been used in the cheekbone area and chin, with deep (sub-periosteal) infiltrations. The results obtained were noted as either satisfactory or very


satisfactory in 98 cases, and in only four cases was it necessary to perform a touch-up 2 weeks after the initial treatment. The percentage of side-effects


was not statistically significant with regard to oedema or erythema, which cleared up spontaneously within the first 2 weeks. Follow-up treatments were


performed at 2 weeks, 3 months and 6 months, and in all patients the filling/lifting result obtained in the last follow-up was noticeably maintained, while an improvement in the quality of the cutis treated both in terms of hydration, compactness and texture was also noted.


ALIAXIN® GP for malar zone enhancement, (A) before and (B) after AMWC Symposium


Professor Giuseppe Sito will be presenting at the AMWC Monaco, 2013


HYDROLIFT™ ACTION: A NEW APPROACH IN FACIAL RESHAPING


16:30–17:30, Thursday 4 April Room Ravel, Level -2


“Thanks to the presence of a gel made up of monophasic hyaluronic acid, it is


possible to achieve an excellent lifting effect of the cutaneous wrinkles.


prime-journal.com | March 2013 ❚ 113


Conclusions Based on the results achieved when using the ALIAXIN® range of products, it is possible to assert that these dermal fillers are in line with the most reliable hyaluronic acid-based fillers on the market, both in terms of efficacy, safety and durability. This is added to the stimulating biological action of ALIAXIN® SR, which allows the restoration of the collagen structure of the dermis, therefore completing the filling treatment with an anti-ageing action.


 Further information info@viscoderm.com


 Please visit us at AMWC Monaco, Ravel Hall, booth M3


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100  |  Page 101  |  Page 102  |  Page 103  |  Page 104  |  Page 105  |  Page 106  |  Page 107  |  Page 108  |  Page 109  |  Page 110  |  Page 111  |  Page 112  |  Page 113  |  Page 114  |  Page 115  |  Page 116  |  Page 117  |  Page 118  |  Page 119  |  Page 120  |  Page 121  |  Page 122  |  Page 123  |  Page 124  |  Page 125  |  Page 126  |  Page 127  |  Page 128  |  Page 129  |  Page 130  |  Page 131  |  Page 132  |  Page 133  |  Page 134  |  Page 135  |  Page 136  |  Page 137  |  Page 138  |  Page 139  |  Page 140